![](https://i.imgur.com/CLvY2jA.png")
After reports said some patients who took Paxlovid rebounded and started feeling symptoms again, the CEO told Bloomberg that patients can take another course, “like you do with antibiotics.”
The FDA isn't on board with the suggestion.
“There is no evidence of benefit at this time for a longer course of treatment … or repeating a treatment course of Paxlovid in patients with recurrent COVID-19 symptoms following completion of a treatment course,” John Farley, M.D., director of the Office of Infectious Diseases, said in a post.
About 80,000 US COVID-19 patients have sought treatment with the antiviral as of April 22, CNBC reports. It’s not clear how many patients have had a COVID-19 rebound after taking the full course of the treatment, but many reports of rebounds have surfaced in the last week, puzzling doctors.
Despite the accolades, it's not in as high demand as anticipated, and it recently was found ineffective for post-exposure protection.
https://www.fiercepharma.com/pharma/fda-...oms-return
The FDA isn't on board with the suggestion.
“There is no evidence of benefit at this time for a longer course of treatment … or repeating a treatment course of Paxlovid in patients with recurrent COVID-19 symptoms following completion of a treatment course,” John Farley, M.D., director of the Office of Infectious Diseases, said in a post.
About 80,000 US COVID-19 patients have sought treatment with the antiviral as of April 22, CNBC reports. It’s not clear how many patients have had a COVID-19 rebound after taking the full course of the treatment, but many reports of rebounds have surfaced in the last week, puzzling doctors.
Despite the accolades, it's not in as high demand as anticipated, and it recently was found ineffective for post-exposure protection.
https://www.fiercepharma.com/pharma/fda-...oms-return
